RePORT China was established and is managed by China TB Clinical Trial Consortium (CTCTC), through close collaboration with the RePORT International Coordinating Center (RICC) at FHI 360. CTCTC is a network of 19 top TB clinical trial sites across China, receiving technical support from FHI 360, funded by the U.S. Division of AIDS (DAIDS), National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The coordinating office of RePORT China is at Beijing Chest Hospital.  Six CTCTC member sites (Beijing, Changsha, Fuzhou, Shanghai, Shenzhen, Wuhan, Zhenjiang) are currently in the pilot stage, enrolling patients with culture-positive pulmonary TB.  Parent projects are two TB trials of drug-sensitive cases funded by China Ministry of Science and Technology, in which patients receive either 6-month standard treatment or a shortened 4.5-month treatment.  Research protocols were adopted in accordance with RePORT International Common Protocol (CP).